Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

J P Thyssen; M S de Bruin-Weller; A S Paller; Y A Leshem; C Vestergaard; M Deleuran; A M Drucker; R Foelster-Holst; C T Hoffmann; K Eyerich; A Taieb; J C Su; T Bieber; M J Cork; L F Eichenfield; E Guttman-Yassky; A Wollenberg

doi:10.1111/jdv.15608

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

J P Thyssen, M S de Bruin-Weller, A S Paller, Y A Leshem, C Vestergaard, M Deleuran, A M Drucker, R Foelster-Holst, C T Hoffmann, K Eyerich, A Taieb, J C Su, T Bieber, M J Cork, L F Eichenfield, E Guttman-Yassky, A Wollenberg

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

49 Citationer (Scopus)

44 Downloads (Pure)

Abstract

BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.

OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).

METHODS: Electronic survey and in-person discussion of management strategies.

RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.

LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.

CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

Originalsprog	Engelsk
Tidsskrift	Journal of the European Academy of Dermatology and Venereology
Vol/bind	33
Udgave nummer	7
Sider (fra-til)	1224-1231
Antal sider	8
ISSN	0926-9959
DOI	https://doi.org/10.1111/jdv.15608
Status	Udgivet - jul. 2019

Adgang til dokumentet

10.1111/jdv.15608Licens: CC BY-NC 4.0

Thyssen_et_al-2019-Journal_of_the_European_Academy_of_Dermatology_and_VenereologyForlagets udgivne version, 167 KBLicens: CC BY-NC 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

http://www.scopus.com/inward/record.url?scp=85065301744&partnerID=8YFLogxK

Citationsformater

Thyssen, J. P., de Bruin-Weller, M. S., Paller, A. S., Leshem, Y. A., Vestergaard, C., Deleuran, M., Drucker, A. M., Foelster-Holst, R., Hoffmann, C. T., Eyerich, K., Taieb, A., Su, J. C., Bieber, T., Cork, M. J., Eichenfield, L. F., Guttman-Yassky, E., & Wollenberg, A. (2019). Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 33(7), 1224-1231. https://doi.org/10.1111/jdv.15608

@article{68861dac9a464799b7e19a5611d1b316,

title = "Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion",

abstract = "BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.",

author = "Thyssen, {J P} and {de Bruin-Weller}, {M S} and Paller, {A S} and Leshem, {Y A} and C Vestergaard and M Deleuran and Drucker, {A M} and R Foelster-Holst and Hoffmann, {C T} and K Eyerich and A Taieb and Su, {J C} and T Bieber and Cork, {M J} and Eichenfield, {L F} and E Guttman-Yassky and A Wollenberg",

year = "2019",

month = jul,

doi = "10.1111/jdv.15608",

language = "English",

volume = "33",

pages = "1224--1231",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Elsevier",

number = "7",

}

Thyssen, JP, de Bruin-Weller, MS, Paller, AS, Leshem, YA, Vestergaard, C, Deleuran, M, Drucker, AM, Foelster-Holst, R, Hoffmann, CT, Eyerich, K, Taieb, A, Su, JC, Bieber, T, Cork, MJ, Eichenfield, LF, Guttman-Yassky, E & Wollenberg, A 2019, 'Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion', Journal of the European Academy of Dermatology and Venereology, bind 33, nr. 7, s. 1224-1231. https://doi.org/10.1111/jdv.15608

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. / Thyssen, J P; de Bruin-Weller, M S; Paller, A S et al.
I: Journal of the European Academy of Dermatology and Venereology, Bind 33, Nr. 7, 07.2019, s. 1224-1231.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

AU - Thyssen, J P

AU - de Bruin-Weller, M S

AU - Paller, A S

AU - Leshem, Y A

AU - Vestergaard, C

AU - Deleuran, M

AU - Drucker, A M

AU - Foelster-Holst, R

AU - Hoffmann, C T

AU - Eyerich, K

AU - Taieb, A

AU - Su, J C

AU - Bieber, T

AU - Cork, M J

AU - Eichenfield, L F

AU - Guttman-Yassky, E

AU - Wollenberg, A

PY - 2019/7

Y1 - 2019/7

N2 - BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

AB - BACKGROUND: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.OBJECTIVE: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).METHODS: Electronic survey and in-person discussion of management strategies.RESULTS: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.LIMITATIONS: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.CONCLUSION: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.

UR - http://www.scopus.com/inward/record.url?scp=85065301744&partnerID=8YFLogxK

U2 - 10.1111/jdv.15608

DO - 10.1111/jdv.15608

M3 - Journal article

C2 - 31056788

SN - 0926-9959

VL - 33

SP - 1224

EP - 1231

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion

Abstract

Adgang til dokumentet

AUB Link

Andre filer og links

Fingeraftryk

Citationsformater